PYXIS ONCOL.INC. DL-,0001 Aktie

Pyxis Oncology published preclinical data showing that a mouse analogue of MICVO (maMICVO) dose-dependently inhibited tumor growth in an HNSCC model, with 6 mg/kg producing the strongest effect. Treatment reduced regulatory T cells and increased the ratio of CD8 T cells to Tregs, and in a model that did not respond to anti‑PD‑1 monotherapy, the combination of maMICVO with anti‑PD‑1 produced synergistic tumor control. MICVO is currently being tested in phase 1 studies as monotherapy and in combination with pembrolizumab; updated study data are planned for mid‑2026 and the second half of 2026. MICVO has FDA Fast Track designation for recurrent/metastatic HNSCC. » Plus sur de.investing.com

Thomas Civik was appointed interim chief executive officer of Pyxis Oncology, succeeding Dr. Lara S. Sullivan, while the board has begun a search for a permanent CEO. The clinically focused biopharma company reportedly has more cash than debt, a current ratio of 4.29 and a market capitalization of about $95 million, but remains unprofitable and is burning cash; the stock traded at $1.53 after a 39% gain over six months. Pyxis is advancing its lead ADC program MICVO in phase 1 monotherapy and phase 1/2 combination studies with pembrolizumab; MICVO has received FDA fast-track designation for recurrent/metastatic head and neck squamous cell carcinoma. » Plus sur de.investing.com

The Pyxis Oncology share price fell about 50% in pre-market trading after investors reacted negatively to preliminary Phase‑1 data for MICVO. The company reported objective response rates of 46% in monotherapy and 71% in combination with Keytruda, but the results were based on very small patient groups (13 and 7 evaluable, respectively). High adverse event rates were also reported (89% treatment-related AEs; 56% grade 3+; 28% treatment discontinuations), and broader data are now expected later (mid‑2026 and the second half of 2026). Pyxis plans an adjusted dosing regimen to improve tolerability and sold licensing rights for $11 million, extending the cash runway into Q4 2026. » Plus sur de.investing.com